Inflammatory bowel disease.
Expert Rev Clin Immunol., Jul;6(4):499-500 (2010)
The role of biologics in ulcerative colitis.
Dig Dis., 28(3):497-500 (2010)
Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
J Crohns Colitis., Feb;5(1):48-53 (2011)
Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis.
J Crohns Colitis., Aug;6(7):756-62 (2012)
Medical management of Crohn's disease: treatment algorithms 2009.
Dig Dis., 27(4):536-41 (2009)
Conventional treatment in inflammatory bowel disease--recent trends. Immunosuppressants and biologic agents: should they or need they be used together? How to use immunosuppressive therapy better (and safer) tomorrow?
Gastroenterol. Clin. Biol., Jun;33 Suppl 3:S202-8 (2009)
African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity.
J. Immunol., Jun;184(12):7001-9 (2010)
Positioning biologic agents in the treatment of Crohn's disease.
Inflamm. Bowel Dis., Oct;15(10):1570-82 (2009)
Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
Aliment. Pharmacol. Ther., Mar;27 Suppl 1:15-21 (2008)
Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Gut., Sep;56(9):1181-3 (2007)
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
Aliment. Pharmacol. Ther., Aug;32(3):384-93 (2010)
Commentary: pre-operative use of anti-TNF-Î± agents and the risk of post-operative complications in patients with ulcerative colitis.
Aliment. Pharmacol. Ther., Jul;36(2):199-200; discussion 200 (2012)
Long-term Treatment of Patients With a History of Ulcerative Colitis Who Develop Gastritis and Pan-Enteritis After Colectomy.
J. Clin. Gastroenterol., Jul (2012)
Two brothers with skewed thiopurine metabolism in ulcerative colitis treated successfully with allopurinol and mercaptopurine dose reduction.
Dig. Dis. Sci., Jan;57(1):250-3 (2012)
Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
J. Pediatr. Gastroenterol. Nutr., Sep;45(3):312-8 (2007)
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
Aliment. Pharmacol. Ther., May;33(10):1143-51 (2011)
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
Can. J. Gastroenterol., Dec;21(12):827-34 (2007)
author, The role of biologics in ulcerative colitis.
co-author, Inflammatory bowel disease.
Expert Review of Clinical Immunology
author, Ashes to ashes.
Nature Reviews Gastroenterology & Hepatology